Cns Pharmaceuticals Inc (CNSP) Stock Experiences -0.81% Monthly Change

The stock of Cns Pharmaceuticals Inc (CNSP) has seen a -18.65% decrease in the past week, with a -0.81% drop in the past month, and a -75.79% decrease in the past quarter. The volatility ratio for the week is 12.71%, and the volatility levels for the past 30 days are at 14.54% for CNSP. The simple moving average for the past 20 days is -20.46% for CNSP’s stock, with a -78.08% simple moving average for the past 200 days.

Is It Worth Investing in Cns Pharmaceuticals Inc (NASDAQ: CNSP) Right Now?

CNSP has 36-month beta value of 1.08. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

The public float for CNSP is 8.03M, and currently, short sellers hold a 1.29% ratio of that float. The average trading volume of CNSP on April 03, 2024 was 408.06K shares.

CNSP) stock’s latest price update

The stock price of Cns Pharmaceuticals Inc (NASDAQ: CNSP) has dropped by -14.54 compared to previous close of 0.36. Despite this, the company has seen a fall of -18.65% in its stock price over the last five trading days. Accesswire reported 2024-04-01 that HOUSTON, TX / ACCESSWIRE / April 1, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) (“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals will present at two upcoming investor conferences being held in New York City in April. In addition to the presentations, management will be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the respective conferences.

Analysts’ Opinion of CNSP

Ladenburg Thalmann, on the other hand, stated in their research note that they expect to see CNSP reach a price target of $11. The rating they have provided for CNSP stocks is “Buy” according to the report published on August 24th, 2020.

CNSP Trading at -13.11% from the 50-Day Moving Average

After a stumble in the market that brought CNSP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -93.01% of loss for the given period.

Volatility was left at 14.54%, however, over the last 30 days, the volatility rate increased by 12.71%, as shares sank -16.80% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -60.57% lower at present.

During the last 5 trading sessions, CNSP fell by -18.65%, which changed the moving average for the period of 200-days by -85.89% in comparison to the 20-day moving average, which settled at $0.3835. In addition, Cns Pharmaceuticals Inc saw -75.79% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at CNSP starting from Climaco John M, who purchase 166,666 shares at the price of $0.30 back on Feb 01 ’24. After this action, Climaco John M now owns 215,676 shares of Cns Pharmaceuticals Inc, valued at $50,000 using the latest closing price.

Downs Christopher, the Chief Financial Officer of Cns Pharmaceuticals Inc, purchase 66,666 shares at $0.30 during a trade that took place back on Feb 01 ’24, which means that Downs Christopher is holding 103,438 shares at $20,000 based on the most recent closing price.

Stock Fundamentals for CNSP

The total capital return value is set at 10.91. Equity return is now at value -1018.78, with -255.54 for asset returns.

Based on Cns Pharmaceuticals Inc (CNSP), the company’s capital structure generated -0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -331.93. The debt to equity ratio resting at -0.02. The interest coverage ratio of the stock is -1434.55.

Currently, EBITDA for the company is -18.87 million with net debt to EBITDA at 0.05. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.23.


To put it simply, Cns Pharmaceuticals Inc (CNSP) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Related Posts